We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.54B
AUM Growth
+$196M
Cap. Flow
-$299M
Cap. Flow %
-11.74%
Top 10 Hldgs %
37.92%
Holding
126
New
21
Increased
16
Reduced
23
Closed
19

Top Buys

Rank Stock Value
1
ADPT
Adeptus Health Inc
ADPT
+$38.6M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$38M
3
DBVT
DBV Technologies
DBVT
+$30M
4
HUM icon
Humana
HUM
+$28.3M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$26.7M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$67.9M
2
SAGE
Sage Therapeutics
SAGE
+$35.7M
3
MCK icon
McKesson
MCK
+$27.5M
4
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$27.4M
5
AET
Aetna Inc
AET
+$25.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Financials 3.21%
3 Industrials 0.75%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPCH icon
51
Option Care Health
OPCH
$3.41B
$7.62M 0.3%
+746,700
New +$7.62M
INCY icon
52
Incyte
INCY
$23.4B
$7.28M 0.29%
+91,000
New +$7.06M
ALIM
53
DELISTED
Alimera Sciences
ALIM
$7.23M 0.28%
391,868
– –
EPZM
54
DELISTED
Epizyme, Inc
EPZM
$6.37M 0.25%
+622,299
New +$6.94M
EPIX
55
DELISTED
ESSA Pharma
EPIX
$6.36M 0.25%
107,858
-21,503
-17% -$1.34M
CASM
56
DELISTED
CAS Medical Systems, Inc.
CASM
$5.89M 0.23%
3,200,000
– –
GI
57
DELISTED
EndoChoice Holdings, Inc.
GI
$5.88M 0.23%
1,198,950
-624,359
-34% -$2.98M
LOXO
58
DELISTED
Loxo Oncology, Inc
LOXO
$5.82M 0.23%
251,000
– –
ZVRA icon
59
Zevra Therapeutics
ZVRA
$755M
$5.65M 0.22%
88,781
– –
ARLZ
60
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$5.43M 0.21%
1,644,583
– –
RIGL icon
61
Rigel Pharmaceuticals
RIGL
$750M
$5.2M 0.2%
233,137
-6,649
-3% -$165K
ARCT icon
62
Arcturus Therapeutics
ARCT
$172M
$4.8M 0.19%
152,845
– –
MYOK
63
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$4.65M 0.18%
374,800
– –
STDY
64
DELISTED
SteadyMed Ltd
STDY
$4.4M 0.17%
1,346,744
– –
NEOS
65
DELISTED
Neos Therapeutics, Inc
NEOS
$4.25M 0.17%
458,332
– –
EYPT icon
66
EyePoint Inc
EYPT
$1.12B
$4.22M 0.17%
149,282
– –
OXFD
67
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$4.18M 0.16%
464,541
– –
SCYX icon
68
SCYNEXIS
SCYX
$42.4M
$3.85M 0.15%
22,165
+11,565
+109% +$3.27M
SRRA
69
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.2M 0.13%
40,218
-34,815
-46% -$6.63M
GNCA
70
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.82M 0.11%
85,907
-12,500
-13% -$458K
VYGR icon
71
Voyager Therapeutics
VYGR
$192M
$2.59M 0.1%
235,294
– –
INFI
72
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$2.58M 0.1%
1,935,942
-2,462,920
-56% -$11.5M
ARDX icon
73
Ardelyx
ARDX
$1.28B
$2.4M 0.09%
275,000
– –
ATXS
74
DELISTED
Astria Therapeutics
ATXS
$2.38M 0.09%
10,726
– –
CLVS
75
DELISTED
Clovis Oncology, Inc.
CLVS
$2.33M 0.09%
+169,506
New +$2.48M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2016 Portfolio in Review

As of Q2 2016, Deerfield Management held 126 positions worth $2.54B, up 8.3% from $2.35B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $299M in Q2 2016, closing 19 positions and reducing 23 holdings. Its most notable exit was GSK, an estimated $67.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials and Industrials.

Against the trend, Deerfield Management opened a new position in Syros Pharmaceuticals, Inc. Common Stock worth $38M.

  • Deerfield Management's largest Q2 2016 buy was Syros Pharmaceuticals, Inc. Common Stock: 209,522 shares worth $38M.
  • Deerfield Management added most to Adeptus Health Inc in Q2 2016, an estimated $38.6M increase.
  • Deerfield Management's biggest Q2 2016 reduction was Aetna Inc, cutting an estimated $25.9M.
  • Deerfield Management fully exited GSK in Q2 2016, selling an estimated $67.9M.
  • Deerfield Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2016.
  • Deerfield Management opened 21 new positions and closed 19 in Q2 2016.
  • Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $2.54B.

Based on Deerfield Management's 13F filing for Q2 2016, filed 15 Aug 2016.